Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramon Garcia-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izquierdo, Izidore S. Lossos, Craig Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, Andras Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

Blood (2020) 136 (21): 2401–2409.

https://doi.org/10.1182/blood.2019004701

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Galina Salogub, MD PhD, Jiri Mayer, MD, Frantisek Folber, MD PhD, Sebastian Grosicki, MD PhD, Aleksander B Skotnicki, MD PhD, Anna Prochwicz, MD, Alexander Myasnikov, MD, Alexander Gural, MD, Oliver Schoenborn-Kellenberger, MSc, Charlie Brindley, PhD, Stefan Knackmuss, PhD, Sylvia Schwarz, PhD, Sandra Schmich, Cassandra Choe-Juliak, MD MS, Andras Strassz, MD, Leila Alland, MD, Michael Doubek, MD PhD

Blood (2018) 132 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2018-99-118136

Published: 2018

Journal Articles

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Nancy L. Bartlett, MD, Robert W. Chen, MD, Eva Domingo-Domenech, MD, Andres Forero-Torres, MD, Ramon Garcia-Sanz, MD PhD, Philippe Armand, MD PhD, Sumana Devata, MD, Antonia Rodriguez Izquierdo, MD, Izidore S. Lossos, MD, Craig B. Reeder, MD, Taimur Sher, MD, Cassandra Choe-Juliak, MD MS, Kim Prier, Sylvia Schwarz, PhD, Andras Strassz, MD, Leila Alland, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2018-99-118506

Published: 2018

Journal Articles

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Animesh Pardanani, MBBS, PhD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, FRACP, PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Kebede Begna, MD, Hiroyuki Yoshitsugu, PhD, Toni Ann Gestone, PhD, Penny Phillips, PhD, Guan Xing, PhD, Gerson Peltz, MD, MPH, Matthew V Lorenzi, PhD, Leila Alland, MD, Adrian Woolfson, BM BCh, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 664.

https://doi.org/10.1182/blood.V122.21.664.664

Published: 2013

Journal Articles

Effects of AMN107, a Novel Aminopyrimidine Tyrosine Kinase Inhibitor, on Human Mast Cells Bearing Wild-Type or Mutated Codon 816 c-kit.

Srdan Verstovsek, MD, PhD, Cem Akin, MD, Giles J. Francis, MD, Manshouri Taghi, MS, BA, Ly Huynh, BS, Paul W. Manley, MD, Leila Alland, MD, Margaret Dugan, PhD, Jorge E. Cortes, MD, Kantarjian M. Hagop, MD

Blood (2005) 106 (11): 3528.

https://doi.org/10.1182/blood.V106.11.3528.3528

Published: 2005

Journal Articles

Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [ 14 C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

Mark Kagan, PhD, Phi Tran, M.Sc, Volker Fischer, PhD, Paula Savage, MS, Tom Smith, BS, Chiaki Tanaka, PhD, Horst Schran, PhD, Milind Narurkar, PhD, PharmD, Leila Alland, MD

Blood (2005) 106 (11): 4887.

https://doi.org/10.1182/blood.V106.11.4887.4887

Published: 2005

Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 497.

https://doi.org/10.1182/blood.V106.11.497.497

Published: 2005

Journal Articles

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Mirna Golemovic, M.S., Miloslav Beran, M.D., Ph.D., Francis Giles, M.D., Taghi Manshouri, M.S.C., Deborah Thomas, M.D., Jorge Cortes, M.D., Paul Manley, M.D., Leila Alland, M.D., Patricia Rae, B.S.C., Margaret Dugan, M.D., Zeev Estrov, M.D., Ralph B. Arlinghaus, Ph.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2004) 104 (11): 2737.

https://doi.org/10.1182/blood.V104.11.2737.2737

Published: 2004

NARROW

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Effects of AMN107, a Novel Aminopyrimidine Tyrosine Kinase Inhibitor, on Human Mast Cells Bearing Wild-Type or Mutated Codon 816 c-kit.

Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [ 14 C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only